Pyxis Oncology Gets Fast Track Designation For PYX-201 In Head And Neck Cancer

(RTTNews) - Pyxis Oncology, Inc. (PYXS) Wednesday said that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to PYX-201, the company's drug candidate for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC).

The FDA's Fast Track designation program is intended to facilitate and expedite the development and review of new drugs in the U.S. for the treatment of a serious or life-threatening condition.

PYX-201 is currently being evaluated in multiple Phase 1 studies in various types of solid tumors.